Serafin Morales Murillo

Krop, IE; Mayer, IA; Ganju, V; Dickler, M; Johnston, S; Morales, SN; Yardley, DA; Melichar, B; Forero-Torres, A; Lee, SC; de Boer, R; Petrakova, K; Vallentin, S; Perez, EA; Piccart, M; Ellis, M; Winer, E; Gendreau, S; Derynck, M; Lackner, M; Levy, G; Qiu, JH; He, J; Schmid, P

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

LANCET ONCOLOGY 17 811-821. 01/06/2016.

[doi:10.1016/S1470-2045(16)00106-6]

Llombart-Cussac, A; Ramos, M; Dalmau, E; Garcia-Saenz, JA; Gonzalez-Farre, X; Murillo, L; Calvo, L; Morales, S; Carañana V; Gonzalez, A; Fernandez-Morales, LA; Moreno, F; Casas, MI; Angulo, MD; Camara, MC; Garcia-Mace, AI; Carrasco, E; Jara-Sanchez, C

Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study

EUROPEAN JOURNAL OF CANCER 58 122-129. 01/05/2016.

[doi:10.1016/j.ejca.2016.01.015]

Gavilá, J.; Lopez-Tarruella, S.; Saura, C.; Muñoz, M.; Oliveira, M.; De la Cruz-Merino, L.; Morales, S.; Alvarez, I.; Virizuela, J.A.; Martin, M.

SEOM clinical guidelines in metastatic breast cancer 2015

CLINICAL & TRANSLATIONAL ONCOLOGY 17 946-955. 01/12/2015.

[doi:10.1007/s12094-015-1476-7]

Llombart-Cussac A; Bermejo B; Villanueva C; Delaloge S; Morales S; Balmaña J; Amillano K; Bonnefoi H; Casas A; Manso L; Roché H; Gonzalez-Santiago S; Gavilá J; Sánchez-Rovira P; Di Cosimo S; Harbeck N; Charpentier E; Garcia-Ribas I; Radosevic-Robin N; Aura C; Baselga J

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer

BREAST CANCER RESEARCH AND TREATMENT 154 351-357. 01/11/2015.

[doi:10.1007/s10549-015-3616-8]

Martín M; González-Rivera M; Morales S; de la Haba-Rodriguez J; González-Cortijo L; Manso L; Albanell J; González-Martín A; González S; Arcusa A; de la Cruz-Merino L; Rojo F; Vidal M; Galván P; Aguirre E; Morales C; Ferree S; Pompilio K; Casas M; Caballero R; Goicoechea U; Carrasco E; Michalopoulos S; Hornberger J; Prat A

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

Current Medical Research and Opinion 31 1129-1137. 01/06/2015.

[doi:10.1185/03007995.2015.1037730]

Gil-Gil, M.J.; Bellet, M.; Morales, S.; Ojeda, B.; Manso, L.; Mesia, C.; Garcia-Martínez, E.; Martinez-Jáñez, N.; Melé, M.; Llombart, A.; Pernas, S.; Villagrasa, P.; Blasco, C.; Baselga, J.

Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study

BREAST CANCER RESEARCH AND TREATMENT 151 597-606. 01/06/2015.

[doi:10.1007/s10549-015-3415-2]

Martín M; Loibl S; von Minckwitz G; Morales S; Martinez N; Guerrero A; Anton A; Aktas B; Schoenegg W; Muñoz M; Garcia-Saenz JÁ; Gil M; Ramos M; Margeli M; Carrasco E; Liedtke C; Wachsmann G; Mehta K; De la Haba-Rodriguez JR

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study

Journal of Clinical Oncology 33 1045-1045. 20/03/2015.

[doi:10.1200/JCO.2014.57.2388]

Salazar, R.; Morales, S.; Gil-Martín, M.; Aguirre, E.; Oaknin, A.; Garcia, M.; Callies, S.; Wickremsinhe, E.R.; Benhadji, K.A.; Llombart, A.

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors

CANCER CHEMOTHERAPY AND PHARMACOLOGY 73 1205-1215. 01/06/2014.

[doi:10.1007/s00280-014-2457-1]

Aguirre, E.; Morales, S.; Llombart, A.

Other malignancies I. breast cancer

Other Malignancies I. Breast Cancer 235-251. 01/01/2014.

Sanchez-Rovira, P.; Segui, M. A.; Llombart, A.; Aranda, E.; Anton, A.; Sanchez, A.; Lomas, M.; Jaen, A.; Fernandez, M.; Porras, I.; Dalmau, E.; Morales, S.; de la Haba-Rodriguez, J.

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

CLINICAL & TRANSLATIONAL ONCOLOGY 15 810-817. 01/10/2013.

[doi:10.1007/s12094-013-1006-4]

Aguirre E; Taberner T; Luaña A; Morales S; Llombart A

Severe thrombocytopenia related to long-term trastuzumab exposure.

Tumori 99 -. 01/01/2013.

[doi:10.1700/1248.13801]

Martin, Miguel; Segui, Miguel A.; Anton, Antonio; Ruiz, Amparo; Ramos, Manuel; Adrover, Encarna; Aranda, Ignacio; Rodriguez-Lescure, Alvaro; Grosse, Regina; Calvo, Lourdes; Barnadas, Agusti; Isla, Dolores; Martinez del Prado, Purificacion; Ruiz Borrego, Manuel; Zaluski, Jerzy; Arcusa, Angels; Munoz, Montserrat; Lopez Vega, Jose M.; Mel, Jose R.; Munarriz, Blanca; Llorca, Cristina; Jara, Carlos; Alba, Emilio; Florian, Jesus; Li, Junfang; Lopez Garcia-Asenjo, Jose A.; Saez, Amparo; Jose Rios, Maria; Almenar, Sergio; Peiro, Gloria; Lluch, Ana; GEICAM 9805 Investigators

Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer.

NEW ENGLAND JOURNAL OF MEDICINE 363 2200-2210. 02/12/2010.

[doi:10.1056/NEJMoa0910320]